Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

H3N2 M2SR influenza vaccine - FluGen

Next Previous
Drug Profile

H3N2 M2SR influenza vaccine - FluGen

Alternative Names: H3N2 vaccine - FluGen; H3N2-M2SR; Influenza A virus vaccine H3N2-FluGen; Redee Flu; RedeeFlu; Sing2016 M2SR H3N2 influenza vaccine

Latest Information Update: 28 Oct 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator FluGen
  • Developer FluGen; National Institute of Allergy and Infectious Diseases
  • Class Influenza A vaccines; Synthetic vaccines; Vaccines; Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Influenza A virus H3N2 subtype

Most Recent Events

  • 28 Oct 2024 No recent reports of development identified for phase-I development in Influenza-A virus H3N2 subtype(In adolescents, In children, In infants, Prevention) in USA (Intranasal)
  • 28 Jun 2024 No recent reports of development identified for phase-I development in Influenza-A virus H3N2 subtype(In the elderly, In adults) in USA (Intranasal)
  • 17 May 2024 National Institute of Allergy and Infectious Diseases terminates phase-I clinical trials in Influenza A virus H3N2 subtype (In infants, In children, In adolescents, Prevention) in USA (Intranasal) due to lack of product and funding (NCT04960397)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top